MedTrace Logo

Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients

NCT03324776 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-06-26

Study results available
· View outcomes & findings →

Summary

To examine the effects of adding prandial Afrezza inhaled insulin to patients with type 2 diabetes who are not controlled after at least 6 months of other diabetes treatments including oral agents, basal insulin, or GLP-1 use.

Conditions

  • Type2 Diabetes

Interventions

DRUG

Afrezza Inhalant Product

Mealtime Ultra-Rapid Acting Insulin

Sponsors & Collaborators

  • Mannkind Corporation

    collaborator INDUSTRY

  • Model Clinical Research LLC

    lead OTHER

Principal Investigators

  • Philip Levin, MD · Senior Director of MODEL Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-16
Primary Completion
2020-06-10
Completion
2020-06-10
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324776 on ClinicalTrials.gov